116 related articles for article (PubMed ID: 32588106)
1. Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens.
Abulfathi AA; Assawasuwannakit P; Donald PR; Diacon AH; Reuter H; Svensson EM
Eur J Clin Pharmacol; 2020 Nov; 76(11):1557-1565. PubMed ID: 32588106
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.
de Kock L; Sy SK; Rosenkranz B; Diacon AH; Prescott K; Hernandez KR; Yu M; Derendorf H; Donald PR
Antimicrob Agents Chemother; 2014 Oct; 58(10):6242-50. PubMed ID: 25114132
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance.
Abulfathi AA; Donald PR; Adams K; Svensson EM; Diacon AH; Reuter H
Br J Clin Pharmacol; 2020 Nov; 86(11):2123-2132. PubMed ID: 32470182
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
van der Laan LE; Garcia-Prats AJ; Schaaf HS; Chirehwa M; Winckler JL; Mao J; Draper HR; Wiesner L; Norman J; McIlleron H; Donald PR; Hesseling AC; Denti P
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0226421. PubMed ID: 35506699
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of Para-Aminosalicylic Acid and Its 2 Major Metabolites: A Potential Relationship to the Development of Gastrointestinal Intolerance.
Adams KT; Donald PR; Abulfathi AA; Diacon AH; Stander MA; Reuter H
J Clin Pharmacol; 2020 Apr; 60(4):489-494. PubMed ID: 31682027
[TBL] [Abstract][Full Text] [Related]
6. N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis.
Sy SK; de Kock L; Diacon AH; Werely CJ; Xia H; Rosenkranz B; van der Merwe L; Donald PR
Antimicrob Agents Chemother; 2015 Jul; 59(7):4129-38. PubMed ID: 25963985
[TBL] [Abstract][Full Text] [Related]
7. Dose regimen of para-aminosalicylic acid gastro-resistant formulation (PAS-GR) in multidrug-resistant tuberculosis.
Kibleur Y; Brochart H; Schaaf HS; Diacon AH; Donald PR
Clin Drug Investig; 2014 Apr; 34(4):269-76. PubMed ID: 24488376
[TBL] [Abstract][Full Text] [Related]
8. Once-daily and twice-daily dosing of p-aminosalicylic acid granules.
Peloquin CA; Berning SE; Huitt GA; Childs JM; Singleton MD; James GT
Am J Respir Crit Care Med; 1999 Mar; 159(3):932-4. PubMed ID: 10051275
[TBL] [Abstract][Full Text] [Related]
9. Para-aminosalicylic acid (PAS) desensitization review in a case of multidrug-resistant pulmonary tuberculosis.
Wilson JW; Kelkar P; Frigas E
Int J Tuberc Lung Dis; 2003 May; 7(5):493-7. PubMed ID: 12757053
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic evaluation of para-aminosalicylic acid granules.
Peloquin CA; Henshaw TL; Huitt GA; Berning SE; Nitta AT; James GT
Pharmacotherapy; 1994; 14(1):40-6. PubMed ID: 8159600
[TBL] [Abstract][Full Text] [Related]
11. Para-aminosalicylic acid: the return of an old friend.
Donald PR; Diacon AH
Lancet Infect Dis; 2015 Sep; 15(9):1091-1099. PubMed ID: 26277036
[TBL] [Abstract][Full Text] [Related]
12. [Clinical pharmacokinetics of para-aminosalicylic acid tablets].
Miroshnichenko II; Sokolova GB; Mokhireva LV
Antibiot Khimioter; 2009; 54(1-2):20-4. PubMed ID: 19499713
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens.
Zhu Y; Zhu L; Davies Forsman L; Paues J; Werngren J; Niward K; Schön T; Bruchfeld J; Xiong H; Alffenaar JW; Hu Y
Antimicrob Agents Chemother; 2023 May; 67(5):e0170022. PubMed ID: 37097151
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis.
Chang MJ; Jin B; Chae JW; Yun HY; Kim ES; Lee YJ; Cho YJ; Yoon HI; Lee CT; Park KU; Song J; Lee JH; Park JS
Int J Antimicrob Agents; 2017 Jun; 49(6):677-687. PubMed ID: 28408267
[TBL] [Abstract][Full Text] [Related]
15. Successful oral desensitization to i.v. para-aminosalicylic acid (PAS) using encapsulated PAS dry substance.
Vesenbeckh SM; Becker J; Huhnt C; Karras B; Bauer TT; Mauch H; Rüssmann H; Schönfeld N
Infection; 2012 Apr; 40(2):199-202. PubMed ID: 21833615
[TBL] [Abstract][Full Text] [Related]
16. Para-aminosalicylic acid plasma concentrations in children in comparison with adults after receiving a granular slow-release preparation.
Liwa AC; Schaaf HS; Rosenkranz B; Seifart HI; Diacon AH; Donald PR
J Trop Pediatr; 2013 Apr; 59(2):90-4. PubMed ID: 23174991
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients.
Tietjen AK; Kroemer N; Cattaneo D; Baldelli S; Wicha SG
Br J Clin Pharmacol; 2022 Feb; 88(4):1835-1844. PubMed ID: 34622478
[TBL] [Abstract][Full Text] [Related]
18. PAS infusion in treatment of multidrug-resistant tuberculosis.
Fodor T; Pataki G; Schrettner M
Int J Tuberc Lung Dis; 2000 Feb; 4(2):187-8. PubMed ID: 10694102
[No Abstract] [Full Text] [Related]
19. Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions.
Peloquin CA; Zhu M; Adam RD; Singleton MD; Nix DE
Ann Pharmacother; 2001 Nov; 35(11):1332-8. PubMed ID: 11724078
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
Hegde PV; Howe MD; Zimmerman MD; Boshoff HIM; Sharma S; Remache B; Jia Z; Pan Y; Baughn AD; Dartois V; Aldrich CC
Eur J Med Chem; 2022 Mar; 232():114201. PubMed ID: 35219151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
